Bosutinib (SKI-606) is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent.It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to Imatinib or develop resistance during treatment.

Additional Information

Synonyms	SKI-606
Product #	B-2208
CAS #	380843-75-4
Chemical Name	4-(2,4-DICHLORO-5-METHOXYANILINO)-6-METHOXY-7-[3-(4-METHYLPIPERAZIN-1-YL)PROPOXY]QUINOLINE-3-CARBONITRILE
Formula	C26H29Cl2N5O3
MW	530.45
Appearance	White to off-white Solid
Purity	99% by HPLC
Solubility	DMSO (30 mg/ml) or EtOH (10 mg/ml)
Melting Point	131-134 °C
Storage Temp	-20°C
Therapeutic Area	Oncological Disorders
Use	Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML)

Additional Information

MDL Number	MFCD07367846
ChemACX	X1450615-5
InChI	InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
SMILES	CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC